Publications by authors named "C A Samaras"
Article Synopsis
- The study focused on patients with relapsed or refractory multiple myeloma (RRMM) who previously received lenalidomide, examining the effectiveness of a treatment combination involving pomalidomide, daratumumab, and dexamethasone (DPd).
- During the trial, a total of 112 patients were treated, with a median overall survival (OS) of 56.7 months after 41.9 months of follow-up, showing promising results.
- The treatment was generally safe, with adverse events leading to discontinuation in a small percentage of patients, suggesting that this combination therapy could be a viable option for RRMM patients needing further treatment post-lenalidomide.
Article Synopsis
- Daratumumab treatment for light chain (AL) amyloidosis can lead to early refractoriness, leaving patients with fewer options if they relapse or respond poorly.
- This study assessed the effectiveness of venetoclax therapy in AL patients with t(11;14) who had previously failed daratumumab, involving 31 subjects.
- Results showed a 97% overall hematologic response to venetoclax, with strong organ responses in patients with cardiac (74%) and renal (46%) involvement, indicating promising potential for venetoclax as a salvage therapy after daratumumab failure.
Article Synopsis
- Multiple myeloma (MM) is a cancer of the plasma cells in the bone marrow that leads to symptoms like anemia, renal issues, and fatigue, but currently available treatments often have limited long-term success and frequent relapses occur.* -
- The development of drug resistance in myeloma cells complicates treatment, making ongoing research into new therapeutic targets and strategies essential for improving patient outcomes.* -
- This article reviews new and emerging treatment options for MM, organized by specific molecular targets like BCMA and CD38, as well as treatments such as immunomodulatory drugs and NK cell therapy.*
Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell-directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi-institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy.
View Article and Find Full Text PDFThe SARS-CoV-2 virus may cause severe infection, which is associated with diverse clinical manifestations. Vitamin D has immunomodulating properties and may enhance the body's defense system against invading pathogenic organisms. The aim was to assess 25(OH)D levels in patients hospitalized for severe infection from the SARS-CoV-2 virus and explore the relationship between 25(OH)D and outcomes.
View Article and Find Full Text PDF